Optimising low-dose methotrexate for rheumatoid arthritis-A review

被引：46
作者：
Lucas, Catherine J. [1 ,2 ,3 ]
Dimmitt, Simon B. [1 ,4 ]
Martin, Jennifer H. [1 ,2 ,3 ]
机构：
[1] Univ Newcastle, Sch Med & Publ Hlth, Discipline Clin Pharmacol, Newcastle, NSW, Australia
[2] Hunter Med Res Inst, Newcastle, NSW, Australia
[3] Hunter New England Local Hlth Dist, Newcastle, NSW, Australia
[4] Univ Western Australia, Fac Hlth & Med Sci, Med Sch, Div Internal Med, Nedlands, WA, Australia
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2019年 / 85卷 / 10期
关键词：
clinical pharmacology; methotrexate; pharmacodynamics; pharmacokinetics; prescribing; rheumatoid arthritis; MODIFYING ANTIRHEUMATIC DRUGS; PULSE METHOTREXATE; SUBCUTANEOUS METHOTREXATE; ORAL METHOTREXATE; DISEASE-ACTIVITY; DOUBLE-BLIND; RISK-FACTORS; POLYGLUTAMATE CONCENTRATIONS; COMBINATION THERAPY; AMERICAN-COLLEGE;
D O I：
10.1111/bcp.14057
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Methotrexate at low doses (5-25 mg/week) is first-line therapy for rheumatoid arthritis. However, there is inter- and intrapatient variability in response, with contribution of variability in concentrations of active polyglutamate metabolites, associated with clinical efficacy and toxicity. Prescribing remains heterogeneous across population groups, disease states and regimens. This review examines current knowledge of dose-response of oral methotrexate in the setting of rheumatoid arthritis, and how this could help inform dosage regimens.
引用
收藏
页码：2228 / 2234
页数：7
相关论文
共 95 条
[71]   EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update [J].
Smolen, Josef S. ;
Landewe, Robert ;
Bijlsma, Johannes ;
Burmester, Gerd ;
Chatzidionysiou, Katerina ;
Dougados, Maxime ;
Nam, Jackie ;
Ramiro, Sofia ;
Voshaar, Marieke ;
van Vollenhoven, Ronald ;
Aletaha, Daniel ;
Aringer, Martin ;
Boers, Maarten ;
Buckley, Chris D. ;
Buttgereit, Frank ;
Bykerk, Vivian ;
Cardiel, Mario ;
Combe, Bernard ;
Cutolo, Maurizio ;
van Eijk-Hustings, Yvonne ;
Emery, Paul ;
Finckh, Axel ;
Gabay, Cem ;
Gomez-Reino, Juan ;
Gossec, Laure ;
Gottenberg, Jacques-Eric ;
Hazes, Johanna M. W. ;
Huizinga, Tom ;
Jani, Meghna ;
Karateev, Dmitry ;
Kouloumas, Marios ;
Kvien, Tore ;
Li, Zhanguo ;
Mariette, Xavier ;
McInnes, Iain ;
Mysler, Eduardo ;
Nash, Peter ;
Pavelka, Karel ;
Poor, Gyula ;
Richez, Christophe ;
van Riel, Piet ;
Rubbert-Roth, Andrea ;
Saag, Kenneth ;
da Silva, Jose ;
Stamm, Tanja ;
Takeuchi, Tsutomu ;
Westhovens, Rene ;
de Wit, Maarten ;
van der Heijde, Desiree .
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (06) :960-977
[72]   Proposal for a new nomenclature of disease-modifying antirheumatic drugs [J].
Smolen, Josef S. ;
van der Heijde, Desiree ;
Machold, Klaus P. ;
Aletaha, Daniel ;
Landewe, Robert .
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) :3-5
[73]  
Sotoudehmanesh R, 2010, Middle East J Dig Dis, V2, P104
[74]   Effects of Changing from Oral to Subcutaneous Methotrexate on Red Blood Cell Methotrexate Polyglutamate Concentrations and Disease Activity in Patients with Rheumatoid Arthritis [J].
Stamp, Lisa K. ;
Barclay, Murray L. ;
O'Donnell, John L. ;
Zhang, Mei ;
Drake, Jill ;
Frampton, Christopher ;
Chapman, Peter T. .
JOURNAL OF RHEUMATOLOGY, 2011, 38 (12) :2540-2547
[75]   Determinants of Red Blood Cell Methotrexate Polyglutamate Concentrations in Rheumatoid Arthritis Patients Receiving Long-Term Methotrexate Treatment [J].
Stamp, Lisa K. ;
O'Donnell, John L. ;
Chapman, Peter T. ;
Zhang, Mei ;
Frampton, Christopher ;
James, Jill ;
Barclay, Murray L. .
ARTHRITIS AND RHEUMATISM, 2009, 60 (08) :2248-2256
[76]   Concomitant use of low-dose methotrexate and NSAIDs and the risk of serious adverse events among patients with rheumatoid arthritis [J].
Svanstrom, Henrik ;
Lund, Marie ;
Melbye, Mads ;
Pasternak, Bjorn .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 (08) :885-893
[77]  
Swierkot J, 2006, PHARMACOL REP, V58, P473
[78]  
Takahashi C, 2017, RMD OPEN, V3, DOI 10.1136/rmdopen-2016-000363
[79]   Use of methotrexate in older patients - A risk-benefit assessment [J].
Tett, SE ;
Triggs, EJ .
DRUGS & AGING, 1996, 9 (06) :458-471
[80]  
THOMPSON RN, 1984, J RHEUMATOL, V11, P760
12345678910